See more : DND Technologies, Inc. (DNDT) Income Statement Analysis – Financial Results
Complete financial analysis of Psyence Group Inc. (PSYGF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Psyence Group Inc., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- Dlaboratory Sweden AB (publ) (DLAB.ST) Income Statement Analysis – Financial Results
- Clean Logistics SE (SD1.DE) Income Statement Analysis – Financial Results
- Astro-century Education&Technology Co.,Ltd (300654.SZ) Income Statement Analysis – Financial Results
- TPG Pace Beneficial Finance Corp. (TPGY-UN) Income Statement Analysis – Financial Results
- STEP Energy Services Ltd. (STEP.TO) Income Statement Analysis – Financial Results
Psyence Group Inc. (PSYGF)
About Psyence Group Inc.
Psyence Group Inc., a life science biotechnology company, engages in the commercial psilocybin mushroom cultivation and production activities. Its natural psilocybin is used for the treatment of a range of mental health disorders and other medical conditions. The company is developing pharmaceutical preparations of psilocybin doses to help heal psychological trauma and diagnosable disorders, including anxiety, depression, post-traumatic stress disorder, and grief and bereavement. It also focuses on the development, distribution, and sale of over-the-counter non psilocybin containing functional mushroom nutraceutical products under the GOODMIND brand. Psyence Group Inc. was founded in 2019 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 97.93K | 92.27K | 52.64K | 24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -97.93K | -92.27K | -52.64K | -24.50K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.58M | 2.30M | 115.94K | 21.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 3.43M | 3.32M | 4.19M | 92.51K | 19.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 152.16K | 253.62K | 146.62K | 131.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.58M | 3.58M | 4.34M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Other Expenses | 0.00 | 5.45K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Cost & Expenses | 5.16M | 5.97M | 4.51M | 92.51K | 19.06K | 45.82K | 19.97K | 54.79K | 14.69K |
| Interest Income | 3.57K | 7.59K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 72.63K | 123.14K | 1.39K | 1.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 92.93K | 92.27K | 52.64K | 24.50K | 206.30K | 171.86K | 161.14K | 52.52K | 22.82K |
| EBITDA | -5.17M | -5.88M | -4.46M | -3.80M | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.16M | -6.09M | -4.59M | -92.51K | -19.06K | -45.82K | -19.97K | -54.79K | -14.69K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -64.28M | -208.35K | -145.07K | -13.45M | 0.00 | 32.50K | 4.00 | 4.00 | -46.00 |
| Income Before Tax | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -6.18K | -83.90K | -8.12M | -206.29K | -171.86K | -161.14K | -52.52K | -22.82K |
| Net Income | -69.45M | -6.08M | -4.60M | -92.51K | -19.06K | -13.32K | -19.97K | -54.79K | -14.74K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| EPS Diluted | -0.52 | -0.07 | -0.05 | 0.00 | -0.01 | -0.02 | -0.04 | -0.11 | -0.03 |
| Weighted Avg Shares Out | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
| Weighted Avg Shares Out (Dil) | 133.34M | 89.01M | 85.53M | 51.21M | 1.67M | 721.50K | 497.22K | 497.22K | 497.22K |
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and wellbeing, is pleased to announce that its NASDAQ-listed associate, Psyence Biomedical...
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorders (SUDs) through exclusive IP licensing agreement with Psylabs for its botanical...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determination Letter”) from the Listing Qualifications Department of The Nasdaq Stock...
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Patient screening to be initiated imminently; first subject expected to be randomized into the study in October Patient screening to be initiated imminently; first subject expected to be randomized into the study in October
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD)
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously announced $25 million equity line of credit (the “ELOC”) with White Lion...
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C....
Source: https://incomestatements.info
Category: Stock Reports